SEC Form 10-K filed by Veradigm Inc.

Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we

Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti